Results 11 to 20 of about 5,903 (227)
The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
Frontiers in Cardiovascular Medicine, 2022 The cardiotoxicity of fluoropyrimidines (FP) [5-Fluorouracil and Capecitabine] is often reported as acute cardiac ischemia with rest typical angina, signs of ischemia at electrocardiogram (ECG), and ventricular kinetics abnormalities.
Linda Cucciniello +5 more
doaj +2 more sources
Fluoropyrimidines affect de novo pyrimidine synthesis impairing biofilm formation in Escherichia coli [PDF]
BiofilmAntivirulence agents are considered a promising strategy to treat bacterial infections. Fluoropyrimidines possess antivirulence and antibiofilm activity against Gram-negative bacteria; however, their mechanism of action is yet unknown.
Srikanth Ravishankar +5 more
doaj +2 more sources
Fluoropyrimidines: A Cardiotoxicity Case for Caution. [PDF]
JACC Case RepFluoropyrimidines are widely used in cancer treatment but can cause cardiac adverse effects.A 57-year-old man with esophageal cancer, receiving fluoropyrimidine-based therapy, was referred for preoperative cardiac evaluation. Abnormal electrocardiogram findings raised concern for ischemia, but coronary angiography ruled out obstructive disease ...
von Stein P, Wörmann J, Pfister R.
europepmc +3 more sources
DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol [PDF]
Farmacia Hospitalaria, 2021 Objective: The main purpose of this study is to evaluate the potential clinical impact of pharmacogenetic testing on the reduction of the toxicity in patients treated with fluoropyrimidines. This will be achieved by comparing the frequency of adverse
Ana Hernández-Guío +5 more
doaj +1 more source
Near Miss or Standard of Care? DPYD Screening for Cancer Patients Receiving Fluorouracil
Current Oncology, 2020 5-fluorouracil (5-FU) and its pro-drug capecitabine are widely used anticancer agents. Most 5-FU catabolism is dependent on dihydropyrimidine dehydrogenase (DPD) encoded by the DPYD gene, and DPYD variants that reduce DPD function increase 5-FU toxicity.
Lauren E. Winquist +3 more
doaj +1 more source
Oral drugs in the treatment of metastatic colorectal cancer
Therapeutic Advances in Medical Oncology, 2021 Colorectal cancer (CRC) is one of the most common forms of cancer, with an estimated 1.36 million new cases and almost 700,000 deaths annually. Approximately 21% of patients with CRC have metastatic disease at diagnosis.
Pilar García-Alfonso +7 more
doaj +1 more source
Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients [PDF]
, 2011 Fluoropyrimidines and oxaliplatin continued to be the mainstay of therapeutic regimens in the treatment of colorectal cancer (CRC). For this reason, pharmacokinetic and metabolism of these drugs were analyzed and the identification of accurate and ...
SILVESTRIS N. +9 more
core +2 more sources
Fluoropyrimidine-induced cardiotoxicity
World Journal of Clinical Oncology, 2020 Cardio-oncology is a discipline based on early screening, monitoring, and treating chemotherapy-induced cardiotoxicity. There are many chemotherapeutics known for their cardiac toxic effects, including fluoropyrimidines. Fluoropyrimidine represents the cornerstone of many types of cancer and each year almost two million cancer patients undergo this ...
Deac, Andrada Larisa +3 more
openaire +2 more sources
Pharmacogenomic tests in Oncology - finding the right dose
Brazilian Journal of Oncology, 2021 A pharmacogenetics/genomics (PGx) anticancer drug testing program is being developed by Kurtz and his group at the Brazilian National Cancer Institute (INCA).
Jeziel Basso, Gilberto Schwartsmann
doaj +1 more source
, 2011 Purpose: To retrospectively evaluate the efficacy and tolerability of mitomycin-C (MMC) in combination with fluoropyrimidines as salvage 3rd -or 4th-line therapy in metastatic colorectal cancer (MCRC ...
ÜNEK, TARKAN +12 more
core +5 more sources